A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Public ClinicalTrials.gov record NCT04856917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris
Study identification
- NCT ID
- NCT04856917
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 123 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 45 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 15, 2021 (Actual)
- Primary completion
- Feb 1, 2022 (Actual)
- Completion
- Mar 29, 2022 (Actual)
- Last update posted
- Sep 22, 2025
2021 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 10-114 | Hot Springs | Arkansas | 71913 | — |
| Site 10-111 | Fountain Valley | California | 92708 | — |
| Site 10-106 | Sherman Oaks | California | 91403 | — |
| Site 10-113 | Sweetwater | Florida | 33172 | — |
| Site 10-108 | Tampa | Florida | 33607 | — |
| Site 10-107 | Tampa | Florida | 33613 | — |
| Site 10-109 | New Orleans | Louisiana | 70119 | — |
| Site 10-112 | New Orleans | Louisiana | 70119 | — |
| Site 10-104 | Detroit | Michigan | 48202 | — |
| Site 10-110 | Portsmouth | New Hampshire | 03801 | — |
| Site 10-105 | Murfreesboro | Tennessee | 37130 | — |
| Site 10-103 | Austin | Texas | 78759 | — |
| Site 10-102 | College Station | Texas | 77845 | — |
| Site 10-101 | San Antonio | Texas | 78213 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04856917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 22, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04856917 live on ClinicalTrials.gov.